WELLESLEY, Mass. -- Coley Pharmaceutical Group, Inc. announced it has been awarded a $16.9 million, five-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH), to support the development of novel immune-activating drugs for defense against bioterror agents.
Entitled "Innate Immune Receptors and Adjuvant Discovery," this contract will be used to expand Coley's proprietary line of TLR Therapeutic products, focusing on basic research and preclinical studies of novel immunostimulatory compounds targeting Toll-like receptors.
Toll-like receptors (TLR's) are a family of receptors found on immune cells that are understood to direct immune response by detecting and recognizing specific classes of pathogens. Coley has previously shown that its TLR Therapeutics targeting TLR9 can stimulate protective immunity against potential bioterror germs such as anthrax. Coley has received two earlier government awards for the discovery and development of advanced biodefense vaccine adjuvants and therapeutics. Together with prior awards, the new contract brings the total committed biodefense funding for Coley to $35 million.
"We have made tremendous progress in the last few years in demonstrating the potential of Coley's immune stimulants to protect against lethal doses of most potential bioterror agents," said Arthur Krieg, MD, senior vice president, R&D, who will be leading Coley's research efforts under the contract. "This contract will facilitate the expansion of our research programs beyond TLR9 agonists to additional targets that activate the immune system in different ways. We believe our research efforts from this and prior grants will enable us to fine-tune potential products designed to defend against infectious agents with or without specific vaccines by regulating immune function."
Source: Coley Pharmaceutical Group
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.